Skip to main content

Table 2 NMA Fixed effects results, SMDs converted to log odds ratios for slowing the decline in FVC

From: The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation

   

Log odds ratios

Odds ratios

Comparator (vs. placebo)

N studies

Total N participants

Mean

95% CrI

Mean

95% CrI

Azathioprine

1

19

0.44

-0.30

1.19

1.56

0.74

3.29

Nintedanib

1

170

-0.97

-1.52

-0.41

0.38

0.22

0.66

NAC triple therapy

2

294

-0.06

-0.60

0.48

0.94

0.55

1.62

Inhaled NAC

1

76

-0.42

-1.24

0.40

0.66

0.29

1.49

Pirfenidone

4

1006

-0.39

-0.62

-0.16

0.68

0.54

0.85

Sildenafil

1

180

-0.12

-0.65

0.41

0.89

0.52

1.51

Head-to-head comparison

       

Nintedanib vs. Pirfenidone

-0.58

  

-1.18

0.03

0.56

0.31

1.03